CommercialPrior AuthLow impact
Kuvan (sapropterin)
Blue Cross & Blue Shield of Mississippi·MS · Pediatrics, Genetics, Endocrinology·Medical Policy
We identified it
Jun 20, 2026
Summary
BCBSMS updated their policy for Kuvan (sapropterin) used to treat phenylketonuria (PKU), maintaining prior authorization requirements with specific criteria for initial evaluation and renewal. The policy requires specialist prescribing and strict dosing parameters within FDA-labeled ranges.
Action Required
Immediately: Billing team should verify that any patients receiving Kuvan (sapropterin) have current prior authorization from BCBSMS. Ensure prescribing providers are specialists in metabolic or genetic diseases and document compliance with all policy criteria including baseline phenylalanine levels and dietary restrictions. Claims without proper prior authorization will be denied.